Ed Schoonveld

Respective industry and government agendas could significantly reshape the US prescription drug market.

Finding the optimal balance in pharmacy benefit manager reform.

Is the potential of a more formal policy integration for health issues and disease prevention a scary suggestion or a good idea?

As the dust settles on the first round of Medicare negotiations, not everything is what it seems.

Balancing innovation focus with optimized decision-making.

The impact of income-based price controls in healthcare.

Fighting for patient affordability doesn’t necessarily require a scapegoat.

The debate continues as to how government payers should weigh covering healthcare needs versus other budget items.

A dive into the issue of evidence gaps, plus the case for a chief access officer.

The latest on its implementation—and the implications for biopharma.

How various factors are affecting the amount of funds allocated to healthcare.

New Pharma Commerce column addresses the relevance of pricing.

Exploring the legislation's diverging requirements between regulatory agencies and global payers, and its impact on the commercial results of biopharma companies

Shared-risk or ‘pay for performance’ agreements between drugmakers and payers can represent uncertain rewards for both parties. Use strategic planning before entering into them